Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials
Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials
复制标题
DOI：
10.1016/j.ejca.2020.10.040
复制
发表时间：
2021-02-01
影响因子：
8.4
通讯作者：
Reijneveld, Jaap C.
中科院分区：
文献类型：
--
作者：
Caramanna, Ivan;Bottomley, Andrew;Reijneveld, Jaap C.
背景资料：据推测，患有脑肿瘤的神经认知受损患者的认知意识降低，使他们无法充分评估和报告自己的功能，例如，在提供患者报告的结果（PRO）时，如健康相关的生活质量工具。在这项横断面研究中，我们的目的是在评估的一致性的神经认知的投诉（NCCs）和客观的神经认知功能（NCF）作为认知awareness.Methods的措施：NCF进行了评估，使用国际公认的临床试验电池。使用来自医学结局研究（MOS）的认知功能问卷和欧洲癌症研究与治疗组织生活质量问卷认知功能子量表评估NCC。根据患者的NCF表现，将患者分为认知受损组和未受损组。计算了NCF和NCC之间的Pearson相关系数。结果：EORTC试验26091和26101的数据被合并到546例患者的数据集。20%的患者可以被描述为未受损（109），80%的患者被描述为受损（437）。受损患者在MOS量表上报告的认知主诉多于未受损患者。NCF和NCC之间的相关性较弱，但对于受损患者来说显着，而对于未受损患者来说不显着。NCF测试性能和QLQ-C30 CF subscale.Conclusion之间的相关性也发现了类似的结果：NCF测试分数和投诉之间的相关性弱，但这表明HGG患者的神经认知功能障碍并不排除认知意识。然而，考虑到这项研究的结果，我们建议不要使用PRO作为基于表现的神经认知评估的替代品。(C)2020作者（S）爱思唯尔有限公司出版
Background: Neurocognitively impaired patients with brain tumour are presumed to have reduced cognitive awareness preventing them from adequately valuing and reporting their own functioning, for instance, when providing patient-reported outcomes (PROs) such as health-related quality of life instruments. In this cross-sectional study, we aimed at assessing the concordance of neurocognitive complaints (NCCs) and objective neurocognitive functioning (NCF) as a measure of cognitive awareness.Methods: NCF was assessed using an internationally accepted clinical trial battery. NCC was assessed using the cognitive functioning questionnaire from the Medical Outcome Study (MOS) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire cognitive functioning subscale. Patients were divided in cognitively impaired and unimpaired groups, based on their NCF performance. Pearson's correlation coefficients between NCF and NCCs were calculated. The same procedure was used to evaluate the correlation of NCF and QLQ-C30 CF subscale.Results: Data from EORTC trials 26091 and 26101 were pooled into a data set of 546 patients. Twenty percent of patients could be characterised as unimpaired (109) and 80% as impaired (437). Impaired patients reported more cognitive complaints on the MOS scale than unimpaired patients. Correlations between NCF and NCCs were weak but significant for impaired patients and non-significant for unimpaired ones. Similar results were found for the correlation between NCF test performance and the QLQ-C30 CF subscale.Conclusion: Correlations between NCF test scores and complaints were weak but suggesting that neurocognitive impairment in patients with HGG does not preclude cognitive awareness. However, considering the findings of this study, we would suggest not to use PROs as a surrogate of performance-based neurocognitive evaluation. (C) 2020 The Author(s). Published by Elsevier Ltd.